Latest News and Press Releases

Trethera and UCLA publish peer-reviewed manuscript highlighting dCK as a novel cancer target and TRE-515 as the first clinically tested dCK inhibitor

Oxford UK, July 16th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces that it has relocated to new, state-of-the-art facilities...

The first patient has been dosed in the intermittent weekly dosing (QW) arm of the ongoing Phase 1 clinical trial of AN9025, a pan-RAS(ON) inhibitor.

Today’s announcements from $NTHI, $ERNA, and $VIVS highlight three distinct pathways to potential value creation.

ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced...

SOTIO's ADC, SOT109, given Fast Track Designation for advanced unresectable or metastatic colorectal cancer who have exhausted standard treatment options.

Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth

Oncolytics announced more than 20 patients pre-identified for REO 033 colorectal cancer trial and scheduled Type D meeting with the FDA.

VERAXA Biotech initiates a collaboration with Ardigen SA to optimize cancer target pair selection for growing BiTAC® pipeline.

Avance Clinical to Showcase Asia and China Growth Strategy at BIO Asia–Taiwan 2026